Margaret Hopson | Strasburger & Price LLP
Across the globe, investigations by regulators of pharmaceutical and biotech companies continue to grow. Companies need to evolve and adapt to reduce risk when conducting business on a global scale. Among the areas of greatest exposure for pharmaceutical and biotech companies conducting business on a multi-national level is the United States Foreign Corrupt Practices Act (FCPA or the Act), which is comprised of two sets of provisions: 1) anti-bribery provisions; and 2) accounting provisions. The anti-bribery provisions of the FCPA, the subject of this article, prohibit companies from bribing foreign officials to obtain or retain business.